PharVision Advisers’s AXIS Capital AXS Stock Holding History

PharVision Advisers’s Portfolio AXS Stock Details AXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,028	Closed	-$217K	–	151
2025 Q4	$217K	Buy	+2,028	New	+$201K	0.11%	492

Other funds holding AXS

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.72B AUM 7.92% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PharVision Advisers's AXS Position: Q1 2026 in Review

PharVision Advisers sold out of AXIS Capital (AXS) in Q1 2026, closing a stake of 2,028 shares — an estimated $217K sold.

PharVision Advisers first reported a position in AXS in Q4 2025 and held it in 1 quarter. The position peaked at $217K in Q4 2025. 466 funds tracked by Wall St. Rank hold AXS as of Q1 2026.

PharVision Advisers reported no remaining AXIS Capital position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 2,028 AXIS Capital shares in Q1 2026, an estimated $217K.
PharVision Advisers first reported a position in AXIS Capital in Q4 2025 and held it in 1 quarter.
PharVision Advisers's AXIS Capital position peaked at $217K in Q4 2025.
466 funds tracked by Wall St. Rank held AXIS Capital as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.